Welcome to our dedicated page for Cardiff Lexingto news (Ticker: CDIX), a resource for investors and traders seeking the latest updates and insights on Cardiff Lexingto stock.
Cardiff Lexington Corporation reports operating and capital-market developments for a healthcare services holding company focused on orthopedic, spine and pain-management platforms. Its current revenue is derived from Nova Ortho and Spine, which operates regional specialty and ancillary orthopedic care centers in Florida and Georgia that provide diagnostic services, surgical services, primary care evaluations, interventional pain management and specialty consultations for traumatic injury patients.
Recurring updates include financial results, patient-volume and procedure mix, facility and clinician additions, activity at Nova Ortho and Spine locations, acquisition strategy for orthopedic practices and related healthcare assets, OTC market status, reverse stock split actions, registration-statement activity and board governance changes.
Cardiff Lexington Corporation (OTC PINK:CDIX) released its pro forma historical profit and loss statement, incorporating its recent acquisition of Nova Ortho and Spine. The acquisition is expected to drive growth as Cardiff Lexington's Healthcare Division adds resources for revenue generation. In 2020, combined revenue reached $7.6 million, up 43% from 2019. Notably, net cash improved by over $1 million, and stockholders' equity increased by $7.2 million. The company's focus remains on a 'Buy and Build' strategy within healthcare and financial services.
Cardiff Lexington Corporation (OTC PINK:CDIX) has acquired Nova Ortho and Spine, LLC, marking the launch of its Healthcare Division. The acquisition, valued at $6,079,334, includes cash and stock components, with a potential performance-based supplement in 2022. Nova Ortho will expand Cardiff's reach in Florida, focusing on integrating complementary healthcare services. With a management team experienced in optimizing growth, the subsidiary expects a 30% internal growth rate as Cardiff Lexington aims to build a robust holding company in niche healthcare markets.
Cardiff Lexington Corporation (CDIX) recently reported its financial results for Q1 2021, revealing a net loss of $1,574,267, a 72% improvement from the previous year's loss of $5,575,757. The loss per share decreased by over 89%, amounting to (5.33), compared to (48.93) in Q1 2020. Notably, the company reported a net positive change of $3,977,394 year-over-year. Additionally, cash and cash equivalents rose to $510,760 from $99,860, highlighting improved liquidity. Cardiff Lexington's management aims to reduce convertible debt and enhance its acquisition strategy in healthcare and financial services.
Cardiff Lexington Corporation (OTC PINK:CDIX) reported its financial results for the year ending December 31, 2020. The company experienced a significant reduction in net loss, decreasing from $6.3 million in 2019 to $2.4 million in 2020, despite challenges posed by the Covid-19 pandemic. Revenue was 93% of 2019 levels. The fair value of derivative liabilities decreased by 22.5%. The company is focusing on future acquisitions in the financial services and healthcare sectors, undergoing due diligence including audits. Management anticipates measurable impacts in 2021.
Cardiff Lexington Corporation (CDIX) reported significant financial improvements for Q3 2020, posting a net income of $2,942,275, a notable recovery from a net loss of $2,990,459 in Q3 2019, marking a net positive change of $5,932,734. For the nine months ending September 30, 2020, the company incurred a net loss of $1,928,552, a substantial improvement from $9,133,106 in 2019, demonstrating a positive change of $7,204,554. Earnings per share jumped to $3.08 from a loss of ($95.89) in the previous year, reflecting strategic financial alignments.